HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.
Trastuzumab has been approved for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction cancers (GC and GJC) in combination with chemotherapy. The aim of this HER2 early/advanced gastric epidemiology (HER-EAGLE) study was to evaluate the frequency of...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science (PLoS)
2013-01-01
|
| Col·lecció: | PLoS ONE |
| Accés en línia: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0080290&type=printable |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
